Sirken G, Raja R, Rizkala A R
Langhorne Nephrology, 183B Bristol Oxford Valley Road, Langhorne, PA 19147, USA.
Clin Nephrol. 2006 Nov;66(5):348-56. doi: 10.5414/cnp66348.
In vitro evidence suggests that different intravenous iron (i.v. Fe) preparations may be associated with different infection rates. This observational study was to determine if different bacteremia rates are associated with different types or amounts of i.v. Fe preparations.
This retrospective, single-center study was carried out from April 2001 November 2002, a period in which a global switch from ferric gluconate (FG) to iron sucrose (IS) occurred. During Period I (April 2001 - January 2002) FG was the only i.v. Fe administered in our hemodialysis unit. During Period II (February 2002 - November 2002) IS was the only i.v. Fe administered in our unit. Group A (n = 63) received hemodialysis during both Period I and Period II. Group B (n = 41) received hemodialysis either during Period I or Period II.
More bacteremic episodes occurred while IS than while FG was being administered. The adjusted bacteremia incidence rate ratios (IRRs) associated with use of IS vs. FG were 2.92 (95% CI, 1.01 - 8.5) and 2.84 (95% CI 1.32 - 6.09) in Groups A and B, respectively. The adjusted bacteremia IRRs associated with receiving > 2,000 mg of i.v. Fe were 2.42 (95% CI 1.03 - 5.6) and 1.54 (95% CI 0.43 - 5.69) in Groups A and B, respectively. Use of catheters as hemodialysis access increased bacteremia risk in both groups.
Use of iron sucrose is associated with higher bacteremia rates than ferric gluconate. The potential association between the cumulative amount of i.v. Fe administered and bacteremia risk is unclear. Randomized clinical trials are needed to verify our findings.
体外证据表明,不同的静脉铁剂制剂可能与不同的感染率相关。本观察性研究旨在确定不同的菌血症发生率是否与不同类型或剂量的静脉铁剂制剂有关。
本回顾性单中心研究于2001年4月至2002年11月进行,在此期间全球范围内从葡萄糖酸铁(FG)转换为蔗糖铁(IS)。在第一阶段(2001年4月至2002年1月),FG是我们血液透析单元中唯一使用的静脉铁剂。在第二阶段(2002年2月至2002年11月),IS是我们单元中唯一使用的静脉铁剂。A组(n = 63)在第一阶段和第二阶段均接受血液透析。B组(n = 41)在第一阶段或第二阶段接受血液透析。
使用IS时发生的菌血症发作比使用FG时更多。在A组和B组中,与使用IS相比使用FG的调整后菌血症发病率比(IRR)分别为2.92(95%CI,1.01 - 8.5)和2.84(95%CI 1.32 - 6.09)。在A组和B组中,与接受>2000mg静脉铁剂相关的调整后菌血症IRR分别为2.42(95%CI 1.03 - 5.6)和1.54(95%CI 0.43 - 5.69)。使用导管作为血液透析通路增加了两组的菌血症风险。
与葡萄糖酸铁相比,蔗糖铁的使用与更高的菌血症发生率相关。静脉铁剂给药的累积量与菌血症风险之间的潜在关联尚不清楚。需要进行随机临床试验来验证我们的发现。